Lineage Cell Therapeutics (LCTX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 10, 2026, with shareholders voting on director elections, auditor ratification, and executive compensation approval.

• Shareholders of record as of April 20, 2026, are eligible to vote, with 249,298,295 common shares outstanding.

• Voting can be done online, by phone, mail, or in person, with cumulative voting allowed for directors.

Voting matters and shareholder proposals

• Seven directors are nominated for election to serve until the 2027 annual meeting.

• Ratification of Baker Tilly US, LLP as the independent auditor for fiscal year 2026 is proposed.

• Advisory approval of executive compensation (say-on-pay) is on the agenda.

• Shareholder proposals and nominations for the next annual meeting must be submitted by specified deadlines and comply with bylaws.

Board of directors and corporate governance

• The board consists of experienced professionals in biotech, pharma, finance, and law.

• Six of seven directors are independent; the CEO is not considered independent.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Financial Strategy.

• The chair and CEO roles are separated to reinforce board independence.

• Directors are required to hold at least 10,000 shares within three years of election.